Diagnosis of chronic lymphoproliferative disorders by flow cytometry using four-color combinations for immunophenotyping: A proposal of the brazilian group of flow cytometry (GBCFLUX)

Imagem de Miniatura
Arquivos
art_SALES_Diagnosis_of_chronic_lymphoproliferative_disorders_by_flow_cytometry_2017.PDF (367.25 KB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
FERREIRA, S. I. A. C. P.
IKOMA, M. R. V.
SANDES, A. F.
BELTRAME, M. P.
BACAL, N. S.
MALVEZZI, M.
LORAND-METZE, I. G. H.
ORFAO, A.
Citação
CYTOMETRY PART B-CLINICAL CYTOMETRY, v.92, n.5, p.398-410, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundMultiparametric flow cytometry (MFC) is a powerful tool for the diagnosis of hematological malignancies and has been useful for the classification of chronic lymphoproliferative disorders (CLPD) according to the WHO criteria. Following the purposes of the Brazilian Group of Flow Cytometry (GBCFLUX), the aim of this report was to standardize the minimum requirements to achieve an accurate diagnosis in CLPDs, considering the different economic possibilities of the laboratories in our country. Most laboratories in Brazil work with 4-fluorescence flow cytometers, which is why the GBCFLUX CLPD Committee has proposed 4-color monoclonal antibody (MoAb) panels. Methods/ResultsPanels for screening and diagnosis in B, T and NK lymphoproliferative disorders were developed based on the normal differentiation pathways of these cells and the most frequent phenotypic aberrations. Important markers for prognosis and for minimal residual disease (MRD) evaluation were also included. The MoAb panels presented here were designed based on the diagnostic expertise of the participating laboratories and an extensive literature review. ConclusionThe 4-color panels presented to aid in the diagnosis of lymphoproliferative neoplasms by GBCFLUX aim to provide clinical laboratories with a systematic, step-wise, cost-effective, and reproducible approach to obtain an accurate immunophenotypic diagnosis of the most frequent of these disorders. (c) 2016 International Clinical Cytometry Society
Palavras-chave
chronic lymphoproliferative disorders, flow cytometry, GBCFLUX, monoclonal antibody panel, lymphoma, multiple myeloma
URI
https://observatorio.fm.usp.br/handle/OPI/22067
Referências
  1. ALMASRI NM, 1992, AM J HEMATOL, V40, P259, DOI 10.1002/ajh.2830400404
  2. Arroz M, 2016, CYTOM PART B-CLIN CY, V90, P31, DOI 10.1002/cyto.b.21228
  3. Barnett D, 2013, CYTOM PART B-CLIN CY, V84, P309, DOI 10.1002/cyto.b.21107
  4. Bataille R, 2008, LEUKEMIA RES, V32, P379, DOI 10.1016/j.leukres.2007.07.016
  5. Beck RC, 2003, AM J CLIN PATHOL, V120, P785, DOI 10.1309/835B04QXGNNFNRJU
  6. Belhadj K, 2003, BLOOD, V102, P4261, DOI 10.1182/blood-2003-05-1675
  7. Boyd SD, 2013, APPL IMMUNOHISTO M M, V21, P116, DOI 10.1097/PAI.0b013e31825d550a
  8. Brachtl G, 2014, ANN HEMATOL, V93, P361, DOI 10.1007/s00277-013-1967-y
  9. CATOVSKY D, 1984, SEMIN ONCOL, V11, P362
  10. Challagundla P, 2014, AM J CLIN PATHOL, V142, P837, DOI [10.1309/AJCPBV9ELXC0ECVL, 10.1309/AJCPBV9ELXCOECVL]
  11. Cho YU, 2013, J KOREAN MED SCI, V28, P542, DOI 10.3346/jkms.2013.28.4.542
  12. Cornet E, 2014, ANN HEMATOL, V93, P1977, DOI 10.1007/s00277-014-2140-y
  13. Craig FE, 2008, BLOOD, V111, P3941, DOI 10.1182/blood-2007-11-120535
  14. Davis BH, 2013, CYTOM PART B-CLIN CY, V84, P286, DOI 10.1002/cyto.b.21105
  15. de Vries ARV, 1999, EUR J IMMUNOL, V29, P3160
  16. Dearden C, 2011, BRIT J HAEMATOL, V152, P273, DOI 10.1111/j.1365-2141.2010.08494.x
  17. Demurtas A, 2013, CYTOM PART B-CLIN CY, V84B, P82, DOI 10.1002/cyto.b.21065
  18. Dimopoulos M, 2011, BLOOD, V117, P4701, DOI 10.1182/blood-2010-10-299529
  19. DiRaimondo F, 2002, CANCER, V94, P1721, DOI 10.1002/cncr.10401
  20. Dong HY, 2003, AM J CLIN PATHOL, V119, P218, DOI 10.1309/U98ADVKUC26R2RJA
  21. Dorwal P, 2014, EGYPT J HAEMATOL, V39, P258
  22. El Desoukey NA, 2012, J INVEST MED, V60, P56, DOI 10.2310/JIM.0b013e31823908f9
  23. Fan L, 2015, LEUKEMIA LYMPHOMA, V56, P3329, DOI 10.3109/10428194.2015.1030642
  24. Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001
  25. Flores-Montero J, 2016, CYTOM PART B-CLIN CY, V90, P61, DOI 10.1002/cyto.b.21265
  26. Frigyesi I, 2014, BLOOD, V123, P1336, DOI 10.1182/blood-2013-09-529800
  27. Healey R, 2015, LEUKEMIA LYMPHOMA, V56, P2619, DOI 10.3109/10428194.2014.999326
  28. Herling M, 2008, BLOOD, V111, P328, DOI 10.1182/blood-2007-07-101519
  29. Ikoma MRV, 2015, CYTOM PART B-CLIN CY, V88, P194, DOI 10.1002/cyto.b.21175
  30. Jamal S, 2001, AM J CLIN PATHOL, V116, P512
  31. Jasionowski TM, 2003, AM J CLIN PATHOL, V120, P228, DOI 10.1309/QVJD31TEG9UJ18BQ
  32. Jiang NG, 2013, ANN HEMATOL, V92, P89, DOI 10.1007/s00277-012-1574-3
  33. Johansson U, 2014, BRIT J HAEMATOL, V165, P455, DOI 10.1111/bjh.12789
  34. Jourdan M, 1998, BRIT J HAEMATOL, V100, P637, DOI 10.1046/j.1365-2141.1998.00623.x
  35. Juco J, 2003, AM J CLIN PATHOL, V119, P205, DOI 10.1309/HEFL7KC435LFWEX8
  36. Kelemen K, 2008, AM J CLIN PATHOL, V129, P146, DOI 10.1309/05GFG3LY3VYCDMEY
  37. Kelemen K, 2010, AM J CLIN PATHOL, V134, P127, DOI 10.1309/AJCP93LJPTRQPDKR
  38. Kempf W, 2006, J CUTAN PATHOL, V33, P58, DOI 10.1111/j.0303-6987.2006.00548.x
  39. Kesler MV, 2007, AM J CLIN PATHOL, V128, P314, DOI 10.1309/GUHKGAJEJ72CEAL7
  40. Kondo S, 1996, LEUKEMIA RES, V20, P357, DOI 10.1016/0145-2126(95)00159-X
  41. Kraus TS, 2010, AM J CLIN PATHOL, V134, P271, DOI 10.1309/AJCPOGCI3DAXVUMI
  42. Landgren O, 2016, CYTOM PART B-CLIN CY, V90, P14, DOI 10.1002/cyto.b.21273
  43. Leith CP, 2001, NEOPLASTIC HEMATOPAT, P255
  44. Lima M, 2004, AM J PATHOL, V165, P1117, DOI 10.1016/S0002-9440(10)63373-1
  45. Lima M, 2003, HAEMATOLOGICA, V88, P874
  46. Lima M, 2015, LEUKEMIA LYMPHOMA, V56, P103, DOI 10.3109/10428194.2014.905772
  47. Lima M, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-95
  48. Lopez-Guillermo A, 2007, ANN ONCOL, V18, P51, DOI 10.1093/annonc/mdm294
  49. Lorand-Metze I, 2015, CYTOM PART B-CLIN CY, V90B, P484, DOI 10.1002/cyto.b.21240
  50. Mateo G, 2008, J CLIN ONCOL, V26, P2737, DOI 10.1200/JCO.2007.15.4120
  51. Matutes E, 2007, J CLIN PATHOL, V60, P1373, DOI 10.1136/jcp.2007.052456
  52. MATUTES E, 1994, LEUKEMIA LYMPHOMA, V14, P57
  53. Matutes E, 2007, BEST PRACT RES CL HA, V20, P367, DOI 10.1016/j.beha.2007.03.001
  54. McCarron KF, 2000, AM J CLIN PATHOL, V113, P805
  55. Moreau P, 2006, BRIT J HAEMATOL, V132, P168, DOI 10.1111/j.1365-2141.2005.05849.x
  56. Mori KL, 2001, BRIT J HAEMATOL, V115, P225, DOI 10.1046/j.1365-2141.2001.03038.x
  57. Morice WG, 2009, MODERN PATHOL, V22, P807, DOI 10.1038/modpathol.2009.34
  58. Mossner M, 2013, J MED GENET, V50, P108, DOI 10.1136/jmedgenet-2012-101093
  59. Muccio VE, 2016, CYTOM PART B-CLIN CY, V90, P81, DOI 10.1002/cyto.b.21279
  60. Oberley MJ, 2014, AM J CLIN PATHOL, V142, P411, DOI 10.1309/AJCP0SWZJ6GBDHPF
  61. Ohgami RS, 2011, LEUKEMIA, V25, P1439, DOI 10.1038/leu.2011.107
  62. Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749
  63. Paiva B, 2012, LEUKEMIA, V26, P1862, DOI 10.1038/leu.2012.42
  64. Paiva B, 2015, BLOOD, V125, P3059, DOI 10.1182/blood-2014-11-568907
  65. Paiva B, 2012, BLOOD, V119, P687, DOI 10.1182/blood-2011-07-370460
  66. Paiva B, 2009, HAEMATOL-HEMATOL J, V94, P1599, DOI 10.3324/haematol.2009.009100
  67. Pan Y, 2016, LEUKEMIA RES, V40, P77, DOI 10.1016/j.leukres.2015.11.003
  68. Perbellini O, 2014, HAEMATOLOGICA, V99, P881, DOI 10.3324/haematol.2013.096362
  69. Perez-Persona E, 2007, BLOOD, V110, P2586, DOI 10.1182/blood-2007-05-088443
  70. Pillai V, 2013, AM J CLIN PATHOL, V140, P536, DOI 10.1309/AJCPEBK31VQQNDDR
  71. Porwit A, 2013, INT J LAB HEMATOL, V35, P275, DOI 10.1111/ijlh.12080
  72. Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487
  73. Rawstron AC, 2008, NEW ENGL J MED, V359, P575, DOI 10.1056/NEJMoa075290
  74. Rawstron AC, 2008, HAEMATOL-HEMATOL J, V93, P431, DOI 10.3324/haematol.11080
  75. Rawstron AC, 2016, CYTOM PART B-CLIN CY, V90, P21, DOI 10.1002/cyto.b.21272
  76. Rawstron AC, 2013, J CLIN ONCOL, V31, P2540, DOI 10.1200/JCO.2012.46.2119
  77. Rimsza LM, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-144
  78. San Miguel JF, 2003, SEMIN ONCOL, V30, P187, DOI 10.1053/sonc.2003.50074
  79. Sanchez ML, 2002, LEUKEMIA, V16, P1460, DOI 10.1038/sj.leu.2402584
  80. Sandes AF, 2014, CYTOM PART B-CLIN CY, V86, P98, DOI 10.1002/cyto.b.21128
  81. Schmidt-Hieber M, 2011, HAEMATOL-HEMATOL J, V96, P328, DOI 10.3324/haematol.2010.031872
  82. Schonberg K, 2012, METHODS MOL BIOL, V903, P381, DOI 10.1007/978-1-61779-937-2_26
  83. Semenzato G, 1997, BLOOD, V89, P256
  84. Shahjahani M, 2015, CELL ONCOL, V38, P93, DOI 10.1007/s13402-014-0215-3
  85. Shao HP, 2013, LEUKEMIA RES, V37, P401, DOI 10.1016/j.leukres.2012.11.021
  86. Stetler-Stevenson M, 2016, CYTOM PART B-CLIN CY, V90, P26, DOI 10.1002/cyto.b.21249
  87. Stetler-Stevenson M, 2007, H43 A2 ED 940 W VALL
  88. Swerdlow SH, 2008, WHO CLASSIFICATION T
  89. Tembhare PR, 2014, LEUKEMIA RES, V38, P371, DOI 10.1016/j.leukres.2013.12.007
  90. Traverse-Glehen A, 2008, BLOOD, V111, P2253, DOI 10.1182/blood-2007-07-098848
  91. van Dongen JJM, 2012, LEUKEMIA, V26, P1899, DOI 10.1038/leu.2012.121
  92. Yu HB, 2009, AM J CLIN PATHOL, V131, P33, DOI 10.1309/AJCP62WRKERPXDRT
  93. Zambello Renato, 2014, Transl Med UniSa, V8, P4

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - ODS/03